Answers are grounded in this paper and cite their sources.
Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.
No takes yet. Share an insight, caveat, or question.
Bent et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: